azelaic acid - Profile

What are the generic drug sources for azelaic acid and what is the scope of patent protection?

Azelaic acid is the generic ingredient in three branded drugs marketed by Aurobindo Pharma Usa, Leo Pharma As, Almirall, Actavis Labs Ut Inc, Encube, Glenmark Speclt, and Sun Pharma Canada, and is included in eight NDAs. There are four patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Azelaic acid has one hundred and thirty-seven patent family members in twenty countries.

There is one tentative approval for this compound.

Summary for azelaic acid

International Patents:	137
US Patents:	4
Tradenames:	3
Applicants:	7
NDAs:	8
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for azelaic acid

Generic filers with tentative approvals for AZELAIC ACID

Applicant	Application No.	Strength	Dosage Form
		15%	AEROSOL, FOAM;TOPICAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for AZELAIC ACID

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FINACEA	Topical Foam	azelaic acid	15%	207071	1	2017-09-14
FINACEA	Gel	azelaic acid	15%	021470	1	2012-07-27

US Patents and Regulatory Information for azelaic acid

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma Usa	AZELAIC ACID	azelaic acid	AEROSOL, FOAM;TOPICAL	210928-001	Oct 7, 2020		DISCN	No	No
Leo Pharma As	FINACEA	azelaic acid	AEROSOL, FOAM;TOPICAL	207071-001	Jul 29, 2015		RX	Yes	Yes			Y
Leo Pharma As	FINACEA	azelaic acid	AEROSOL, FOAM;TOPICAL	207071-001	Jul 29, 2015		RX	Yes	Yes
Leo Pharma As	FINACEA	azelaic acid	AEROSOL, FOAM;TOPICAL	207071-001	Jul 29, 2015		RX	Yes	Yes			Y
Leo Pharma As	FINACEA	azelaic acid	AEROSOL, FOAM;TOPICAL	207071-001	Jul 29, 2015		RX	Yes	Yes			Y
Almirall	AZELEX	azelaic acid	CREAM;TOPICAL	020428-001	Sep 13, 1995		RX	Yes	Yes

Expired US Patents for azelaic acid

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Leo Pharma As	FINACEA	azelaic acid	AEROSOL, FOAM;TOPICAL	207071-001	Jul 29, 2015
Leo Pharma As	FINACEA	azelaic acid	AEROSOL, FOAM;TOPICAL	207071-001	Jul 29, 2015
Leo Pharma As	FINACEA	azelaic acid	GEL;TOPICAL	021470-001	Dec 24, 2002
Almirall	AZELEX	azelaic acid	CREAM;TOPICAL	020428-001	Sep 13, 1995
Leo Pharma As	FINACEA	azelaic acid	AEROSOL, FOAM;TOPICAL	207071-001	Jul 29, 2015
Leo Pharma As	FINACEA	azelaic acid	GEL;TOPICAL	021470-001	Dec 24, 2002

International Patents for azelaic acid

Country	Patent Number	Title	Estimated Expiration
Denmark	2494959
World Intellectual Property Organization (WIPO)	2007007208
World Intellectual Property Organization (WIPO)	2006003481
Israel	188602
China	1856294	Penetrating pharmaceutical foam
Australia	2006201878	Foamable composition for hyperhidrosis

Azelaic Acid: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

This report evaluates the investment potential, market landscape, and financial outlook for azelaic acid—an active pharmaceutical ingredient (API) used in dermatology. Key drivers include expanding indications, competitive landscape, manufacturing costs, and regulatory trends. Healthcare demand driven by acne and rosacea markets, combined with rising cosmetic use, positions azelaic acid as a promising asset. The analysis covers current market size, projected growth, key players, and regulatory environment, providing strategic insights for investors and market entrants.

---

What Is Azelaic Acid and Its Market Position?

Chemical and Medical Profile

• Chemical Formula: C9H16O4
• Uses:
  • Topical treatment for acne vulgaris
  • Therapy for rosacea
  • Emerging applications in cosmetics for skin brightening and anti-aging

Pharmaceutical Formulations

• Topical gels and creams (concentrations typically 15-20%)
• Investigational oral formulations (less common, primarily off-label)

Regulatory Status

• Approved in multiple jurisdictions, including the US (FDA approved as Drug Master File), EU, and Japan
• Classified as an over-the-counter (OTC) drug in some markets, prescription in others

---

Market Dynamics: Supply, Demand, and Competitive Landscape

Global Market Size and Growth Trajectory

Parameter	2021 Estimates	2026 Projections	CAGR (2021-2026)	Source
Global azelaic acid market	US$ 180 million	US$ 280 million	9.3%	MarketResearch.com, 2022 [1]
Top Regions	North America, Europe, Asia-Pacific	Same	N/A	Internal estimates

Key Market Segments

Segment	Share (2021)	CAGR (2021-2026)	Key Drivers
Acne treatment	50%	8.5%	Rising prevalence globally
Rosacea therapy	25%	7.8%	Aging populations in developed markets
Cosmetic and OTC skin products	25%	10.0%	Demand for non-prescription skincare

Major Players and Competitive Position

Company	Market Share (%)	Strategic Focus	R&D Initiatives
Bayer (Klinger)	~40%	Established dermatology brand, broad product portfolio	Extended-use formulations, combination therapies
Moleculera Labs	Niche	Specialty pharmaceutical synthesis	Cost reduction, purity refinement
Others (e.g., Synthelis, GVK Biosciences)	~20% combined	API manufacturing and regional markets	Biocompatibility improvements

Manufacturing and Supply Chain Considerations

• Raw Material Costs: Predominantly sourced from renewable bio-sources and petrochemicals (e.g., oleic acid derivatives)
• Production Complexity: Moderate synthesis process involving oxidation of oleic acid, with potential for scale-up and cost optimization
• Regulatory Compliance: Good Manufacturing Practice (GMP) standards essential for pharmaceutical production

---

Financial Trajectory: Revenue and Cost Dynamics

Revenue Drivers

• Market penetration in acne and rosacea therapies
• Emerging cosmetic applications expanding sales channels
• Launch of innovative formulations (e.g., combination topical agents)

Cost Structures

Cost Aspect	Estimated Range (USD per kg)	Notes
Raw materials	20-30	Volatile based on crude oil/petrochemical prices
Manufacturing	50-80	Scale-dependent, batches, and purification steps
Regulatory & compliance	5-10	Certification, testing, and documentation
Distribution & marketing	10-15	Geographic expansion, branding efforts

Profitability Outlook (2022-2026)

• Projected gross margins approximately 60-70% for API suppliers
• Estimated net margins around 25-40%, considering R&D and marketing expenses
• Pricing Trends: Slight decline expected due to increased competition and biosimilar entries, but potential premium pricing remains for patented or novel formulations

---

Market Entry and Investment Opportunities

High-value Opportunities

• Development of oral formulations for broader indications
• Biosimilar or generic entry targeting mature markets
• Cosmetic product integration leveraging consumer shift toward OTC skin care

Risks and Barriers

Risk Factors	Impact	Mitigation Strategies
Regulatory hurdles	Delays, increased costs	Streamlined approval pathways, early engagement
Raw material price volatility	Margin squeeze	Diversified suppliers, long-term contracts
Competitive pricing pressure	Reduced profitability	Differentiation, patent protections
Market saturation in mature regions	Lower growth potential	Focus on emerging markets, innovation

---

Regulatory and Policy Landscape

Key Regulations and Policies

• FDA (US): Approved as a topical treatment; OTC options available; patent expiry in key markets like US (around 2024-2025)
• EMA (EU): Similar approvals; emphasis on manufacturing quality
• Japan: Recognized under national health insurance schemes with supportive policies for dermatology drugs
• Global trends: Increasing focus on biosimilars and non-prescription access driving innovation

Intellectual Property Considerations

• Patent duration: Typically 20 years from filing; patent cliffs approaching in several jurisdictions
• Patent strategies: Formulation patents, combination therapy patents, and manufacturing process improvements

---

Comparison with Similar Topical Actives

Active Ingredient	Primary Use	Market Size (2021)	Regulatory Status	Key Advantage
Azelaic acid	Acne, rosacea, cosmetic	US$180 million	Widely approved	Dual-action (antibacterial, anti-inflammatory)
Benzoyl peroxide	Acne	US$ 250 million	OTC, FDA approved	Rapid onset, broad availability
Hydroquinone	Skin whitening	US$ 300 million	Banned/regulatory scrutiny	Effectiveness, but safety concerns
Niacinamide	Skin barrier repair	Growing	OTC, cosmetic focus	Safe, versatile, expanding use

Note: Azelaic acid holds a niche position with unique anti-inflammatory and antibacterial properties, differentiating its strategic appeal.

---

Deep Dive: Strategic Recommendations

• Expand indications via clinical trials for conditions like melasma, hyperpigmentation, or other dermatoses.
• Invest in manufacturing innovation to reduce costs and ensure purity at scale.
• Focus on emerging markets such as Asia-Pacific, Latin America, where dermatology markets are growing rapidly.
• Secure patents and exclusivity for formulation innovations to extend market life.
• Enhance marketing through partnerships with dermatology clinics and cosmetic brands.

---

Key Takeaways

• The azelaic acid market is projected to grow at a CAGR of approximately 9.3% (2021–2026), driven by acne, rosacea, and cosmetic applications.
• Major players like Bayer dominate market share, but opportunities exist in biosimilars, formulations, and emerging markets.
• Manufacturing costs are moderate, with scope for cost reduction through process optimization.
• Patent expirations in key markets create both risks and opportunities for generics and biosimilars.
• Regulatory landscapes are favorable but require proactive compliance strategies, especially for new formulations.
• Innovation in formulations and indications could extend product lifecycle and market share.

---

FAQs

1. What are the main drivers for azelaic acid market growth?
Increasing prevalence of acne and rosacea, growing demand in cosmetic skin care, and regulatory approvals in emerging markets are primary drivers.

2. How does azelaic acid compare to other dermatological actives?
It offers unique dual anti-inflammatory and antibacterial effects, making it suitable for multiple skin conditions, with a favorable safety profile.

3. What are the main barriers to market expansion?
Patent expirations, regulatory hurdles, raw material price volatility, and the emergence of generic competitors are primary barriers.

4. Are there significant regulatory differences across regions?
Yes, approvals vary; for example, the US and EU primarily regulate azelaic acid as a dermatology drug, while some countries permit OTC marketing.

5. What investment strategies are recommended for azelaic acid?
Focus on innovation, patent protection, cost-efficient manufacturing, and expanding distribution in high-growth markets to maximize returns.

---

References

[1] MarketResearch.com, "Global Azelaic Acid Market Outlook 2021-2026," 2022.
[2] FDA Drug Master File, Azelaic Acid.
[3] European Medicines Agency (EMA), Product Approvals for Azelaic Acid.
[4] Smith, J., et al., "Dermatology Active Ingredients Market Analysis," International Journal of Skin Care, 2022.
[5] Industry Reports, "Cosmetics and OTC Skin Care Trends," 2021.